SiBone (NASDAQ:SIBN – Get Free Report) and Inogen (NASDAQ:INGN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for SiBone and Inogen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SiBone | 1 | 0 | 5 | 0 | 2.67 |
| Inogen | 1 | 1 | 1 | 0 | 2.00 |
SiBone presently has a consensus target price of $25.00, suggesting a potential upside of 48.81%. Inogen has a consensus target price of $11.00, suggesting a potential upside of 82.42%. Given Inogen’s higher probable upside, analysts clearly believe Inogen is more favorable than SiBone.
Insider & Institutional Ownership
Earnings & Valuation
This table compares SiBone and Inogen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SiBone | $167.18 million | 4.36 | -$30.91 million | ($0.51) | -32.94 |
| Inogen | $335.70 million | 0.49 | -$35.89 million | ($1.01) | -5.97 |
SiBone has higher earnings, but lower revenue than Inogen. SiBone is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
SiBone has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.
Profitability
This table compares SiBone and Inogen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SiBone | -11.24% | -12.86% | -9.43% |
| Inogen | -7.31% | -13.21% | -8.30% |
Summary
SiBone beats Inogen on 8 of the 14 factors compared between the two stocks.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
About Inogen
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
